Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly
Apr 16
Hong Kong (HSI) Biotech Industry Analysis
UpdatedApr 19, 2024
DataAggregated Company Financials
Companies47
- 7D-6.5%
- 3M-6.2%
- 1Y-45.4%
- YTDn/a
Over the last 7 days, the Biotech industry has dropped 6.1%, driven by Innovent Biologics declining 8.5%. Meanwhile, Lepu Biopharma actually outperformed within the industry, gaining 14% in the last week. However, the industry is down 47% over the past year. Looking forward, earnings are forecast to grow by 35% annually.
Industry Valuation and Performance
Has the Hong Kong Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 19 Apr 2024 | HK$322.4b | HK$49.6b | -HK$19,911,350,266.52 | 10.8x | -16.2x | 6.5x |
| Sun, 17 Mar 2024 | HK$366.5b | HK$47.2b | -HK$20,445,921,301.34 | 17.6x | -17.9x | 7.8x |
| Tue, 13 Feb 2024 | HK$321.6b | HK$46.8b | -HK$20,175,287,948.53 | 15.6x | -15.9x | 6.9x |
| Thu, 11 Jan 2024 | HK$382.9b | HK$46.9b | -HK$20,242,897,600.00 | 18x | -18.9x | 8.2x |
| Sat, 09 Dec 2023 | HK$399.9b | HK$46.9b | -HK$20,242,488,582.00 | 17.7x | -19.8x | 8.5x |
| Mon, 06 Nov 2023 | HK$413.3b | HK$45.2b | -HK$18,919,413,159.00 | 12.9x | -21.8x | 9.2x |
| Wed, 04 Oct 2023 | HK$400.6b | HK$45.0b | -HK$19,139,886,127.00 | 13.7x | -20.9x | 8.9x |
| Fri, 01 Sep 2023 | HK$390.1b | HK$43.5b | -HK$16,489,702,446.00 | 15x | -23.7x | 9x |
| Sun, 30 Jul 2023 | HK$427.8b | HK$35.5b | -HK$23,380,251,031.00 | 28x | -18.3x | 12x |
| Tue, 27 Jun 2023 | HK$393.4b | HK$35.4b | -HK$23,246,705,446.00 | 24.9x | -16.9x | 11.1x |
| Thu, 25 May 2023 | HK$426.2b | HK$36.1b | -HK$23,813,255,373.00 | 29.5x | -17.9x | 11.8x |
| Sat, 22 Apr 2023 | HK$441.4b | HK$37.0b | -HK$24,142,920,851.00 | 18.5x | -18.3x | 11.9x |
| Mon, 20 Mar 2023 | HK$405.8b | HK$32.4b | -HK$35,346,503,379.00 | 22.9x | -11.5x | 12.5x |
| Wed, 15 Feb 2023 | HK$440.1b | HK$34.8b | -HK$35,187,293,822.00 | 31.4x | -12.5x | 12.6x |
| Fri, 13 Jan 2023 | HK$444.2b | HK$34.9b | -HK$35,324,662,057.00 | 28.7x | -12.6x | 12.7x |
| Sun, 11 Dec 2022 | HK$393.0b | HK$33.6b | -HK$33,953,988,397.00 | 24.6x | -11.6x | 11.7x |
| Tue, 08 Nov 2022 | HK$364.0b | HK$33.8b | -HK$32,491,041,863.00 | 18.5x | -11.2x | 10.8x |
| Thu, 06 Oct 2022 | HK$298.5b | HK$34.0b | -HK$32,534,977,825.00 | 19x | -9.2x | 8.8x |
| Sat, 03 Sep 2022 | HK$332.7b | HK$34.5b | -HK$33,849,516,320.00 | 15.6x | -9.8x | 9.6x |
| Mon, 01 Aug 2022 | HK$328.6b | HK$32.9b | -HK$46,359,653,984.00 | 13x | -7.1x | 10x |
| Wed, 29 Jun 2022 | HK$387.5b | HK$33.1b | -HK$46,680,283,718.00 | 15.3x | -8.3x | 11.7x |
| Fri, 27 May 2022 | HK$321.4b | HK$34.3b | -HK$46,256,256,982.00 | 12.8x | -6.9x | 9.4x |
| Sun, 24 Apr 2022 | HK$331.6b | HK$35.8b | -HK$45,369,217,033.00 | 12.9x | -7.3x | 9.3x |
| Tue, 22 Mar 2022 | HK$325.4b | HK$34.8b | -HK$33,336,593,534.00 | 13.3x | -9.8x | 9.4x |
| Thu, 17 Feb 2022 | HK$311.6b | HK$31.2b | -HK$31,981,474,931.00 | 12.6x | -9.7x | 10x |
| Sat, 15 Jan 2022 | HK$379.3b | HK$31.1b | -HK$31,825,549,632.00 | 13.3x | -11.9x | 12.2x |
| Mon, 13 Dec 2021 | HK$480.7b | HK$31.1b | -HK$31,827,233,997.00 | 13.5x | -15.1x | 15.5x |
| Wed, 10 Nov 2021 | HK$447.8b | HK$30.9b | -HK$31,620,779,940.00 | 13.8x | -14.2x | 14.5x |
| Fri, 08 Oct 2021 | HK$497.1b | HK$30.5b | -HK$31,550,708,496.00 | 15.3x | -15.8x | 16.3x |
| Sun, 05 Sep 2021 | HK$529.2b | HK$30.2b | -HK$32,058,827,347.35 | 17.5x | -16.5x | 17.5x |
| Tue, 03 Aug 2021 | HK$569.8b | HK$30.2b | -HK$32,058,827,347.35 | 13.4x | -17.8x | 18.9x |
| Fri, 07 May 2021 | HK$572.9b | HK$27.8b | -HK$26,637,487,691.09 | 16.9x | -21.5x | 20.6x |
Price to Earnings Ratio
-21.5x
Current Industry PE
- Investors are pessimistic on the Hong Kong Biotechnology industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 11.9x is higher than the industry's current PS ratio of 6.5x.
Past Earnings Growth
- The earnings for companies in the Biotechnology industry have improved over the last three years.
- Revenues for these companies have grown 21% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Comparison
How does Hong Kong Biotech compare with similar industries?
| HK Market | -1.99% | |
| Healthcare | -4.33% | |
| Biotech | -6.46% | |
| Biotech | -6.46% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2157 Lepu Biopharma | HK$4.30 | 13.8% +HK$862.9m | -19.2% | PS29.3x | |
| 2511 HighTide Therapeutics | HK$5.06 | 19.1% +HK$417.0m | n/a | PB3.4x | |
| 2315 Biocytogen Pharmaceuticals (Beijing) | HK$7.12 | 16.3% +HK$399.4m | -71.2% | PS3.7x | |
| 3681 SinoMab BioScience | HK$1.90 | 10.5% +HK$196.5m | 4.4% | PS436.5x | |
| 2105 Laekna | HK$5.60 | 6.3% +HK$128.7m | n/a | PS4295.8x |
